A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.
Pembrolizumab monotherapy improves overall
survival (OS) and cancer control compared with platinum-based chemotherapy in
patients with untreated locally advanced or metastatic programmed death-ligand
1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11
or KEAP1 mutation status, according to results of the phase III
The oral PARP inhibitor talazoparib significantly improves patient-reported outcomes (PROs), but not overall survival (OS), compared with physician’s choice of chemotherapy (PCT) in patients with locally advanced or metastatic HER2-negative breast cancer with a germline BRCA1/2 mutation, final results of the phase III EMBRACA trial have shown.
Atezolizumab, given in combination with enzalutamide, did not show improvement in overall survival (OS) or cancer control compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC), resulting in early termination of the phase III IMbassador250 study.
Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.
The use of durvalumab in combination with olaparib and paclitaxel significantly improves pathological complete response (pCR) rate vs paclitaxel alone in patients with high-risk HER2-negative stage II/III breast cancer, new results of the I-SPY 2 trial have shown.